Community protocol
Third-partyVIP 10mg
- 01Reconstitution solution
- 3 mL
- 02Dose
- 0.1 mg
- 03Syringe units
- 3 units
- 04Frequency
- 7x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- 3 mL
- 07Bottle size
- 10 mg
- 08Bottles needed
- 1
VIP
A 28-amino-acid neuropeptide with wide-ranging effects on lung, gut and immune tissue. Trialled as aviptadil in severe COVID-19 with results that did not support approval.
Overview
VIP is found throughout the gut and lungs, where it relaxes smooth muscle, drives secretion and dampens inflammation. It is especially concentrated in the type II cells of the lung that produce surfactant, which is why it became a candidate for severe respiratory failure. As a drug it is called aviptadil, and it was given emergency evaluation during COVID-19. The trial results were mixed and did not lead to approval.
A 28-amino-acid member of the secretin/glucagon superfamily, acting at the class B GPCRs VPAC1 and VPAC2 and, weakly, at PAC1. Gs coupling raises cAMP, producing bronchodilation, vasodilation, intestinal secretion and inhibition of NF-κB-driven cytokine production. Concentrated in alveolar type II cells where it upregulates surfactant production and inhibits caspase-3-mediated apoptosis, the rationale for the aviptadil ARDS programme. Plasma half-life is roughly 1–2 minutes, requiring continuous infusion. The ACTIV-3b and companion trials in critical COVID-19 did not establish a clear survival benefit.
Research areas
ARDSPulmonary inflammationSarcoidosisChronic inflammatory response
Community-specified data
Community dosage information
Community protocol
Third-partyVIP Nasal Spray
- 01Reconstitution solution
- Not specified
- 02Dose
- 0.2 mg
- 03Syringe units
- 2 units
- 04Frequency
- 7x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- Not specified
- 07Bottle size
- 10 mg
- 08Bottles needed
- Not specified
Source note: 2 sprays per dose. No reconstitution needed.
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Escalating intravenous infusion of 50, 100 then 150 pmol/kg/hour over 12 hours daily for 3 days in critical COVID-19 | Aviptadil ARDS trial protocol |
| Inhaled VIP in pulmonary arterial hypertension in small open studies | Petkov et al., Journal of Clinical Investigation 2003 |
Trial status
Phase 2/3 in critical COVID-19 completed without establishing benefit. Small studies in pulmonary hypertension and sarcoidosis.
Reported safety signals
- Hypotension and diarrhoea are the expected dose-limiting effects, both direct consequences of the mechanism.
- Flushing and tachycardia are common during infusion.
- Intranasal use for "chronic inflammatory response syndrome" is widely promoted but has no controlled trial support at all.
- Very short half-life makes any non-infusion route pharmacologically questionable.
Common questions
Is intranasal VIP effective for chronic inflammatory response syndrome?
There is no controlled trial supporting it. The protocol circulating for that use comes from a single clinical practice, not from published randomised evidence, and VIP's one-to-two-minute half-life makes sustained systemic effect from nasal dosing pharmacologically difficult to justify.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →